DK3325482T3 - Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater - Google Patents
Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater Download PDFInfo
- Publication number
- DK3325482T3 DK3325482T3 DK16745598.9T DK16745598T DK3325482T3 DK 3325482 T3 DK3325482 T3 DK 3325482T3 DK 16745598 T DK16745598 T DK 16745598T DK 3325482 T3 DK3325482 T3 DK 3325482T3
- Authority
- DK
- Denmark
- Prior art keywords
- cytotoxic
- preparation
- methods
- benzodiazepin
- derivatives
- Prior art date
Links
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 0 CC(C)(*)CN(CCOCCOCCOC)c1cc(CO)cc(CO)c1 Chemical compound CC(C)(*)CN(CCOCCOCCOC)c1cc(CO)cc(CO)c1 0.000 description 19
- ROVBYDCETXMZLN-UHFFFAOYSA-N COc(c(O)c1)cc2c1N=CC(Cc1c3cccc1)N3C2=O Chemical compound COc(c(O)c1)cc2c1N=CC(Cc1c3cccc1)N3C2=O ROVBYDCETXMZLN-UHFFFAOYSA-N 0.000 description 2
- ROVBYDCETXMZLN-NSHDSACASA-N COc(c(O)c1)cc2c1N=C[C@H](Cc1c3cccc1)N3C2=O Chemical compound COc(c(O)c1)cc2c1N=C[C@H](Cc1c3cccc1)N3C2=O ROVBYDCETXMZLN-NSHDSACASA-N 0.000 description 2
- WHOMMAJWTHZVJY-WRXSAAJRSA-N CC([C@H](C1)N2c3c1cccc3)Nc(cc(c(OC)c1)O)c1C2=O Chemical compound CC([C@H](C1)N2c3c1cccc3)Nc(cc(c(OC)c1)O)c1C2=O WHOMMAJWTHZVJY-WRXSAAJRSA-N 0.000 description 1
- KJPKSKLKLWGIOS-UHFFFAOYSA-N COc(c(OCc1cc([N+]([O-])=O)cc(CO)c1)c1)cc(C(C2)=O)c1N=CC1C2c2ccccc2C1 Chemical compound COc(c(OCc1cc([N+]([O-])=O)cc(CO)c1)c1)cc(C(C2)=O)c1N=CC1C2c2ccccc2C1 KJPKSKLKLWGIOS-UHFFFAOYSA-N 0.000 description 1
- DYPFZHNLKQOLFG-LXWOLXCRSA-N C[C@@H](C(N[C@@H](C)C(Nc1cc(CCl)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)=O)=O)NC(CCCCC(OC)=O)=O Chemical compound C[C@@H](C(N[C@@H](C)C(Nc1cc(CCl)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)=O)=O)NC(CCCCC(OC)=O)=O DYPFZHNLKQOLFG-LXWOLXCRSA-N 0.000 description 1
- MYVRXOUKNZBDNS-UWVGGRQHSA-N C[C@@H](C(N[C@@H](C)C(Nc1cc(CO)cc(CO)c1)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(Nc1cc(CO)cc(CO)c1)=O)=O)NC MYVRXOUKNZBDNS-UWVGGRQHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195023P | 2015-07-21 | 2015-07-21 | |
| US201662327973P | 2016-04-26 | 2016-04-26 | |
| PCT/US2016/043414 WO2017015502A1 (en) | 2015-07-21 | 2016-07-21 | Methods of preparing cytotoxic benzodiazepine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3325482T3 true DK3325482T3 (da) | 2020-09-28 |
Family
ID=56557925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16745961.9T DK3325483T3 (da) | 2015-07-21 | 2016-07-21 | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
| DK16745598.9T DK3325482T3 (da) | 2015-07-21 | 2016-07-21 | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16745961.9T DK3325483T3 (da) | 2015-07-21 | 2016-07-21 | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
Country Status (22)
| Country | Link |
|---|---|
| US (11) | US9890179B2 (da) |
| EP (7) | EP4286387A3 (da) |
| JP (8) | JP6858745B2 (da) |
| KR (5) | KR20180038460A (da) |
| CN (5) | CN113087763A (da) |
| AU (7) | AU2016297087B2 (da) |
| CA (4) | CA2991305C (da) |
| CY (2) | CY1122553T1 (da) |
| DK (2) | DK3325483T3 (da) |
| ES (4) | ES2933376T3 (da) |
| HK (3) | HK1252322A1 (da) |
| HR (1) | HRP20201479T1 (da) |
| HU (1) | HUE051541T2 (da) |
| IL (10) | IL283355B (da) |
| LT (2) | LT3325483T (da) |
| PL (2) | PL3325482T3 (da) |
| PT (2) | PT3325482T (da) |
| RS (2) | RS59806B1 (da) |
| RU (3) | RU2018105752A (da) |
| SG (2) | SG10202106529XA (da) |
| SI (2) | SI3325482T1 (da) |
| WO (3) | WO2017015496A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180038460A (ko) | 2015-07-21 | 2018-04-16 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체의 제조 방법 |
| CN118099068A (zh) | 2016-03-22 | 2024-05-28 | Ev 集团 E·索尔纳有限责任公司 | 用于衬底的接合的装置和方法 |
| AU2017345454A1 (en) | 2016-10-19 | 2019-05-30 | Invenra Inc. | Antibody constructs |
| MX2019007019A (es) | 2016-12-22 | 2019-08-16 | Univ Degli Studi Magna Graecia Catanzaro | Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer. |
| PL3573948T3 (pl) | 2017-01-25 | 2023-01-30 | Immunogen, Inc. | Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny |
| CN113227127A (zh) | 2018-06-05 | 2021-08-06 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| SG11202104423XA (en) * | 2018-11-12 | 2021-05-28 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| JP7437395B2 (ja) | 2018-11-12 | 2024-02-22 | イミュノジェン・インコーポレーテッド | 細胞傷害性ベンゾジアゼピン誘導体の調製方法 |
| WO2020205564A1 (en) * | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3763183A (en) | 1972-07-10 | 1973-10-02 | Sterling Drug Inc | 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines |
| US3860600A (en) | 1972-07-10 | 1975-01-14 | Sterling Drug Inc | Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines |
| US4678784A (en) | 1984-04-11 | 1987-07-07 | Mcneilab, Inc. | Method for the treatment of LHRH diseases and conditions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| AU757510C (en) | 1998-08-27 | 2003-09-11 | Medimmune Limited | Pyrrolobenzodiazepines |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
| US6548042B2 (en) * | 2000-08-07 | 2003-04-15 | Arstad Erik | Bis-phosphonate compounds |
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| EP1534674A4 (en) | 2002-08-02 | 2007-11-28 | Immunogen Inc | CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE |
| AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| RU2338747C2 (ru) | 2003-03-31 | 2008-11-20 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| ATE421967T1 (de) | 2003-03-31 | 2009-02-15 | Council Scient Ind Res | Nichtvernetzende pyrroloä2,1-cüä1, 4übenzodiazepine als potentielle antitumor- agentien und ihre herstellung |
| DE60324607D1 (de) | 2003-03-31 | 2008-12-18 | Council Scient Ind Res | Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür |
| RU2314309C2 (ru) | 2003-03-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
| WO2005063759A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific And Industrial Research | PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA2558195C (en) * | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| GB0412492D0 (en) * | 2004-06-04 | 2004-07-07 | Sterix Ltd | Compound |
| CA2604805C (en) | 2005-04-21 | 2014-05-27 | Spirogen Limited | Pyrrolobenzodiazepines |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2007039752A1 (en) | 2005-10-05 | 2007-04-12 | Spirogen Limited | Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| CN102702194A (zh) * | 2005-12-21 | 2012-10-03 | 雅培制药有限公司 | 抗病毒化合物 |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| DE112007000079B4 (de) | 2006-02-13 | 2015-08-13 | Council Of Scientific & Industrial Research | Neuartige Bis-Pyrrolo[2,1-c][1,4]benzodiazepin-anthrachinon Konjugate und ein Verfahren zu deren Herstellung |
| WO2007140371A2 (en) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| ES2435779T3 (es) | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
| WO2009016647A1 (en) | 2007-08-01 | 2009-02-05 | Council Of Scientific & Industrial Research | Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent |
| US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0822260D0 (en) | 2008-12-05 | 2009-01-14 | Merten Christoph | Assay |
| WO2010077101A2 (ko) * | 2008-12-30 | 2010-07-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| RU2545080C2 (ru) | 2009-02-05 | 2015-03-27 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
| IN2012DN02780A (da) | 2009-10-06 | 2015-09-18 | Immunogen Inc | |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| WO2011071078A1 (ja) * | 2009-12-08 | 2011-06-16 | 国立大学法人岐阜大学 | 芳香族化合物、並びに、それを用いたオリゴヌクレオチド誘導体合成用修飾担体、オリゴヌクレオチド誘導体及びオリゴヌクレオチド構築物 |
| US8962279B2 (en) * | 2009-12-30 | 2015-02-24 | Intel Corporation | Solid-phase chelators and electronic biosensors |
| RS58523B1 (sr) * | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
| KR20220017432A (ko) | 2010-02-24 | 2022-02-11 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
| US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| PL2675479T3 (pl) * | 2011-02-15 | 2016-09-30 | Cytotoksyczne pochodne benzodiazepiny | |
| CN102234253B (zh) * | 2011-06-02 | 2013-07-03 | 重庆莱美药业股份有限公司 | 一种制备非布索坦中间体的方法 |
| EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| EP3052464B1 (en) * | 2013-10-04 | 2020-04-15 | Novartis AG | 3'end caps for rna-interferring agents for use in rna interference |
| CN104628772A (zh) * | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
| CN103664896B (zh) * | 2013-11-25 | 2016-03-02 | 济南精合医药科技有限公司 | 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法 |
| SG11201701565PA (en) * | 2014-09-03 | 2017-03-30 | Immunogen Inc | Conjugates comprising cell-binding agents and cytotoxic agents |
| TWI757759B (zh) | 2014-09-03 | 2022-03-11 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| KR20180038460A (ko) | 2015-07-21 | 2018-04-16 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체의 제조 방법 |
| DK3380525T3 (da) * | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
-
2016
- 2016-07-21 KR KR1020187005040A patent/KR20180038460A/ko unknown
- 2016-07-21 EP EP23183947.3A patent/EP4286387A3/en active Pending
- 2016-07-21 CN CN202110366892.7A patent/CN113087763A/zh active Pending
- 2016-07-21 CN CN201680053093.1A patent/CN108026103B/zh active Active
- 2016-07-21 IL IL283355A patent/IL283355B/en unknown
- 2016-07-21 CA CA2991305A patent/CA2991305C/en active Active
- 2016-07-21 EP EP16748205.8A patent/EP3325485B1/en active Active
- 2016-07-21 AU AU2016297087A patent/AU2016297087B2/en active Active
- 2016-07-21 PL PL16745598T patent/PL3325482T3/pl unknown
- 2016-07-21 SI SI201630923T patent/SI3325482T1/sl unknown
- 2016-07-21 KR KR1020187003181A patent/KR102659706B1/ko active IP Right Grant
- 2016-07-21 CA CA2992082A patent/CA2992082A1/en active Pending
- 2016-07-21 KR KR1020187005041A patent/KR102660070B1/ko active IP Right Grant
- 2016-07-21 RU RU2018105752A patent/RU2018105752A/ru not_active Application Discontinuation
- 2016-07-21 RS RS20191647A patent/RS59806B1/sr unknown
- 2016-07-21 EP EP22195446.4A patent/EP4163284A1/en not_active Withdrawn
- 2016-07-21 JP JP2018502785A patent/JP6858745B2/ja active Active
- 2016-07-21 CN CN202110219412.4A patent/CN113004288A/zh active Pending
- 2016-07-21 IL IL294651A patent/IL294651B2/en unknown
- 2016-07-21 EP EP20181645.1A patent/EP3778602B1/en active Active
- 2016-07-21 ES ES19200626T patent/ES2933376T3/es active Active
- 2016-07-21 CN CN201680053120.5A patent/CN108055844A/zh active Pending
- 2016-07-21 EP EP16745961.9A patent/EP3325483B1/en active Active
- 2016-07-21 SG SG10202106529XA patent/SG10202106529XA/en unknown
- 2016-07-21 SI SI201630578T patent/SI3325483T1/sl unknown
- 2016-07-21 CA CA2991326A patent/CA2991326A1/en not_active Abandoned
- 2016-07-21 ES ES16745961T patent/ES2764548T3/es active Active
- 2016-07-21 KR KR1020247012816A patent/KR20240055894A/ko active Search and Examination
- 2016-07-21 WO PCT/US2016/043406 patent/WO2017015496A1/en active Application Filing
- 2016-07-21 WO PCT/US2016/043402 patent/WO2017015495A1/en active Application Filing
- 2016-07-21 SG SG10202009354SA patent/SG10202009354SA/en unknown
- 2016-07-21 ES ES20181645T patent/ES2959741T3/es active Active
- 2016-07-21 US US15/216,517 patent/US9890179B2/en not_active Expired - Fee Related
- 2016-07-21 EP EP16745598.9A patent/EP3325482B1/en active Active
- 2016-07-21 US US15/216,512 patent/US9873708B2/en active Active
- 2016-07-21 RU RU2018105609A patent/RU2746322C2/ru active
- 2016-07-21 CA CA3227588A patent/CA3227588A1/en active Pending
- 2016-07-21 DK DK16745961.9T patent/DK3325483T3/da active
- 2016-07-21 LT LTEP16745961.9T patent/LT3325483T/lt unknown
- 2016-07-21 CN CN201680051138.1A patent/CN108290895B/zh active Active
- 2016-07-21 JP JP2018502791A patent/JP6787995B2/ja active Active
- 2016-07-21 RU RU2018105756A patent/RU2727151C2/ru active
- 2016-07-21 PL PL16745961T patent/PL3325483T3/pl unknown
- 2016-07-21 HU HUE16745598A patent/HUE051541T2/hu unknown
- 2016-07-21 AU AU2016297608A patent/AU2016297608B2/en active Active
- 2016-07-21 US US15/216,548 patent/US10081640B2/en active Active
- 2016-07-21 EP EP19200626.0A patent/EP3653628B1/en active Active
- 2016-07-21 IL IL305989A patent/IL305989A/en unknown
- 2016-07-21 KR KR1020247012991A patent/KR20240055903A/ko active Search and Examination
- 2016-07-21 LT LTEP16745598.9T patent/LT3325482T/lt unknown
- 2016-07-21 WO PCT/US2016/043414 patent/WO2017015502A1/en active Application Filing
- 2016-07-21 ES ES16745598T patent/ES2820358T3/es active Active
- 2016-07-21 IL IL305279A patent/IL305279A/en unknown
- 2016-07-21 RS RS20201132A patent/RS60840B1/sr unknown
- 2016-07-21 JP JP2018502800A patent/JP2018522018A/ja not_active Withdrawn
- 2016-07-21 DK DK16745598.9T patent/DK3325482T3/da active
- 2016-07-21 PT PT167455989T patent/PT3325482T/pt unknown
- 2016-07-21 PT PT167459619T patent/PT3325483T/pt unknown
- 2016-07-21 IL IL286788A patent/IL286788B2/en unknown
- 2016-07-21 AU AU2016297607A patent/AU2016297607A1/en not_active Abandoned
-
2017
- 2017-12-11 US US15/837,832 patent/US10370389B2/en active Active
-
2018
- 2018-01-03 US US15/860,864 patent/US10392407B2/en not_active Expired - Fee Related
- 2018-01-11 IL IL256854A patent/IL256854A/en unknown
- 2018-01-11 IL IL256860A patent/IL256860B/en active IP Right Grant
- 2018-01-11 IL IL256861A patent/IL256861B/en active IP Right Grant
- 2018-09-10 HK HK18111602.7A patent/HK1252322A1/zh unknown
- 2018-09-10 HK HK18111603.6A patent/HK1252323A1/zh unknown
- 2018-09-10 HK HK18111601.8A patent/HK1252321A1/zh unknown
- 2018-09-12 US US16/129,008 patent/US10899775B2/en active Active
-
2019
- 2019-06-06 US US16/433,117 patent/US10787463B2/en active Active
- 2019-06-21 US US16/448,261 patent/US20200017526A1/en not_active Abandoned
- 2019-12-30 CY CY20191101364T patent/CY1122553T1/el unknown
-
2020
- 2020-08-10 IL IL276630A patent/IL276630B/en active IP Right Grant
- 2020-08-10 IL IL276631A patent/IL276631B/en unknown
- 2020-08-12 US US16/991,700 patent/US11420982B2/en active Active
- 2020-09-16 HR HRP20201479TT patent/HRP20201479T1/hr unknown
- 2020-09-23 CY CY20201100899T patent/CY1123390T1/el unknown
- 2020-10-28 JP JP2020180147A patent/JP6995178B2/ja active Active
- 2020-11-23 US US17/101,942 patent/US20210171547A1/en active Pending
-
2021
- 2021-03-24 JP JP2021049502A patent/JP7337114B2/ja active Active
- 2021-04-20 AU AU2021202403A patent/AU2021202403B2/en active Active
- 2021-05-17 AU AU2021203148A patent/AU2021203148B2/en active Active
- 2021-12-14 JP JP2021202215A patent/JP7334228B2/ja active Active
-
2022
- 2022-12-14 US US18/080,973 patent/US20230257400A1/en active Pending
-
2023
- 2023-03-03 AU AU2023201339A patent/AU2023201339A1/en active Pending
- 2023-04-11 AU AU2023202221A patent/AU2023202221A1/en active Pending
- 2023-08-16 JP JP2023132536A patent/JP2023162264A/ja not_active Withdrawn
- 2023-08-22 JP JP2023134420A patent/JP2023166434A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3189056T3 (da) | Cytotoksiske benzodiazepinderivater | |
| DK3325482T3 (da) | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
| DK3237045T3 (da) | Indretning til indgivelse af lægemidler | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK3383436T3 (da) | Forbedret fremgangsmåde til fremstilling af indocyaningrønt | |
| DK3191406T3 (da) | Fremgangsmåde til fremstilling af aluminiumchloridderivater | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3166611T3 (da) | Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer | |
| DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3573948T3 (da) | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid | |
| DK3148993T3 (da) | Fremgangsmåde til fremstilling af thiazolderivater | |
| DK3020358T3 (da) | Fremgangsmåde til fremstilling af tandprotese | |
| DK3148976T3 (da) | Fremgangsmåde til fremstilling af dihydroisoxazolderivater | |
| DK3558951T3 (da) | Fremgangsmåde til fremstillingen af delmopinol | |
| DK3500572T3 (da) | Cytisinderivater til behandling af afhængighed | |
| DK3325489T3 (da) | Asymmetrisk fremgangsmåde til fremstilling af thien-indolderivater |